Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

16.9K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.9K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

10.4K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
10.4K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.9K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.

PloS one·2026
Same author

3'UTR regulation of axon translation and optic nerve regeneration.

Molecular neurodegeneration·2026
Same author

Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.

JAMA dermatology·2026
Same author

Predicting treatment intolerance in operable head and neck cancer using the modified head and neck surgery risk index.

Oral oncology·2026
Same author

Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma.

International journal of radiation oncology, biology, physics·2026
Same author

Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: Apr 12, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.6K

Hodgkin lymphoma, version 2.2015.

Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai

    Journal of the National Comprehensive Cancer Network : JNCCN
    |May 13, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Classical Hodgkin lymphoma (CHL) treatment involves chemotherapy and PET/CT scans for response assessment. Brentuximab vedotin shows promise for relapsed/refractory cases, with long-term follow-up being crucial.

    More Related Videos

    Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
    08:31

    Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

    Published on: September 12, 2025

    1.0K
    Enhancing Tumor Content through Tumor Macrodissection
    10:04

    Enhancing Tumor Content through Tumor Macrodissection

    Published on: February 12, 2022

    12.9K

    Related Experiment Videos

    Last Updated: Apr 12, 2026

    Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
    08:53

    Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

    Published on: June 10, 2017

    10.6K
    Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
    08:31

    Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

    Published on: September 12, 2025

    1.0K
    Enhancing Tumor Content through Tumor Macrodissection
    10:04

    Enhancing Tumor Content through Tumor Macrodissection

    Published on: February 12, 2022

    12.9K

    Area of Science:

    • Hematology
    • Oncology

    Background:

    • Hodgkin lymphoma (HL) is a rare cancer of the lymphatic system.
    • Classical Hodgkin lymphoma (CHL) is the most common subtype in Western countries.

    Purpose of the Study:

    • To outline the standard initial treatment for newly diagnosed CHL.
    • To discuss the role of brentuximab vedotin in relapsed or refractory CHL.
    • To emphasize the importance of long-term follow-up after treatment.

    Main Methods:

    • Standard initial treatment includes chemotherapy or combined modality therapy.
    • Restaging with PET/CT using Deauville criteria assesses treatment response.
    • Brentuximab vedotin is a CD30-directed antibody-drug conjugate used in relapsed/refractory settings.

    Main Results:

    • Standard therapy followed by PET/CT is the current approach for newly diagnosed CHL.
    • Brentuximab vedotin has shown encouraging results in relapsed or refractory CHL.
    • Long-term effects of treatment necessitate ongoing patient monitoring.

    Conclusions:

    • The standard treatment for newly diagnosed CHL involves chemotherapy and response assessment via PET/CT.
    • Brentuximab vedotin offers a viable option for patients with relapsed or refractory disease.
    • Long-term follow-up is essential to manage potential treatment sequelae.